In stroke models, GLP-1R agonists reduce infarct size and edema, partly by dampening microglial/astrocyte inflammation and by direct neurotrophic support [110], e.g., GLP-1RA treatment decreases brain MPO (a neutrophil marker) and pro-inflammatory cytokines in ischemia [105,106,110]. The gene discussed is GLP1R; the disease is Stroke.